Sacituzumab tirumotecan (Sac-TMT) approved for marketing for third indication by the National Medical Products Administration...

TQB2102 HER2 bispecific ADC included in the Breakthrough Therapeutic Designation process

Mabwell’s CDH17-targeting ADC 7MW4911 receives IND clearance from NMPA

DualityBio DB-1324 project received clinical trial approval from HREC and TGA in Australia

Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio

Hansoh Pharma grants Roche an exclusive license to novel CDH17-targeting ADC HS-20110